Empagliflozin in Patients with Chronic Kidney Disease
2022; Massachusetts Medical Society; Volume: 388; Issue: 2 Linguagem: Inglês
10.1056/nejmoa2204233
ISSN1533-4406
AutoresWilliam G. Herrington, Natalie Staplin, Christoph Wanner, Jennifer B. Green, Sibylle J. Hauske, Jonathan Emberson, David Preiss, Parminder K. Judge, Kaitlin J. Mayne, Sarah Y A Ng, Emily Sammons, Doreen Zhu, Michael Hill, Will Stevens, Karl Wallendszus, Susanne Brenner, Alfred K. Cheung, Zhihong Liu, Jing Li, Lai Seong Hooi, Wen Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinya Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Dan Massey, Jens Eilbracht, Martina Brueckmann, Martin Landray, Colin Baigent, Richard Haynes,
Tópico(s)Chronic Kidney Disease and Diabetes
ResumoThe effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients.
Referência(s)